Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 495

1.

Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer.

du Bois A, Floquet A, Kim JW, Rau J, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P.

J Clin Oncol. 2014 Sep 15. pii: JCO.2014.55.7348. [Epub ahead of print]

PMID:
25225436
[PubMed - as supplied by publisher]
2.

Long-Term Sexual Functioning in Women After Surgical Treatment of Cervical Cancer Stages IA to IB: A Prospective Controlled Study.

Aerts L, Enzlin P, Verhaeghe J, Poppe W, Vergote I, Amant F.

Int J Gynecol Cancer. 2014 Sep 9. [Epub ahead of print]

PMID:
25180463
[PubMed - as supplied by publisher]
3.

Reproducibility of lymphoscintigraphic evaluation of the upper limb.

Devoogdt N, Van den Wyngaert T, Bourgeois P, Lambrechts M, Van Kampen M, De Groef A, Geraerts I, Neven P, Vergote I, Tjalma W, Christiaens MR, Stroobants S.

Lymphat Res Biol. 2014 Sep;12(3):175-84. doi: 10.1089/lrb.2013.0034. Epub 2014 Aug 21.

PMID:
25144836
[PubMed - in process]
4.

Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.

Kelemen LE, Terry KL, Goodman MT, Webb PM, Bandera EV, McGuire V, Rossing MA, Wang Q, Dicks E, Tyrer JP, Song H, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Timorek A, Menon U, Gentry-Maharaj A, Gayther SA, Ramus SJ, Narod SA, Risch HA, McLaughlin JR, Siddiqui N, Glasspool R, Paul J, Carty K, Gronwald J, Lubiński J, Jakubowska A, Cybulski C, Kiemeney LA, Massuger LF, van Altena AM, Aben KK, Olson SH, Orlow I, Cramer DW, Levine DA, Bisogna M, Giles GG, Southey MC, Bruinsma F, Kjaer SK, Høgdall E, Jensen A, Høgdall CK, Lundvall L, Engelholm SA, Heitz F, du Bois A, Harter P, Schwaab I, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Thompson PJ, Lurie G, Wilkens LR, Lambrechts D, Van Nieuwenhuysen E, Lambrechts S, Vergote I, Beesley J; AOCS Study Group/ACS Investigators, Fasching PA, Beckmann MW, Hein A, Ekici AB, Doherty JA, Wu AH, Pearce CL, Pike MC, Stram D, Chang-Claude J, Rudolph A, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Bogdanova N, Antonenkova N, Odunsi K, Edwards RP, Kelley JL, Modugno F, Ness RB, Karlan BY, Walsh C, Lester J, Orsulic S, Fridley BL, Vierkant RA, Cunningham JM, Wu X, Lu K, Liang D, Hildebrandt MA, Weber RP, Iversen ES, Tworoger SS, Poole EM, Salvesen HB, Krakstad C, Bjorge L, Tangen IL, Pejovic T, Bean Y, Kellar M, Wentzensen N, Brinton LA, Lissowska J, Garcia-Closas M, Campbell IG, Eccles D, Whittemore AS, Sieh W, Rothstein JH, Anton-Culver H, Ziogas A, Phelan CM, Moysich KB, Goode EL, Schildkraut JM, Berchuck A, Pharoah PD, Sellers TA, Brooks-Wilson A, Cook LS, Le ND.

Mol Nutr Food Res. 2014 Jul 28. doi: 10.1002/mnfr.201400068. [Epub ahead of print]

PMID:
25066213
[PubMed - as supplied by publisher]
5.

Indications, techniques and outcomes for pelvic exenteration in gynecological malignancy.

Kaur M, Joniau S, D'Hoore A, Vergote I.

Curr Opin Oncol. 2014 Sep;26(5):514-20. doi: 10.1097/CCO.0000000000000109.

PMID:
25050632
[PubMed - in process]
6.

A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery.

Vergote I, Oaknin A, Baurain JF, Ananda S, Wong S, Su X, Wu B, Zhong Z, Warner D, Casado A.

Eur J Cancer. 2014 Sep;50(14):2408-16. doi: 10.1016/j.ejca.2014.06.010. Epub 2014 Jul 15.

PMID:
25037684
[PubMed - in process]
7.

HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma.

Kalogiannidis I, Petousis S, Bobos M, Margioula-Siarkou C, Topalidou M, Papanikolaou A, Vergote I, Agorastos T.

Arch Gynecol Obstet. 2014 Jul 15. [Epub ahead of print]

PMID:
25022554
[PubMed - as supplied by publisher]
8.

A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.

Vergote I, Schilder RJ, Pippitt CH Jr, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix L, Leach JW, Ananda S, Nanayakkara N, Melara R, Bass MB, Litten J, Adewoye H, Wenham RM.

Gynecol Oncol. 2014 Jul 11. pii: S0090-8258(14)01078-6. doi: 10.1016/j.ygyno.2014.07.003. [Epub ahead of print]

PMID:
25019569
[PubMed - as supplied by publisher]
9.

Prognostic Value of Serum HE4 Levels and Risk of Ovarian Malignancy Algorithm Scores at the Time of Ovarian Cancer Diagnosis.

Kaijser J, Van Belle V, Van Gorp T, Sayasneh A, Vergote I, Bourne T, Van Calster B, Timmerman D.

Int J Gynecol Cancer. 2014 Sep;24(7):1173-80. doi: 10.1097/IGC.0000000000000181.

PMID:
24987915
[PubMed - in process]
10.

Reply to B. Freidlin et al.

Vergote I, Coens C, Casado A, Jimeno A.

J Clin Oncol. 2014 Aug 1;32(22):2388. doi: 10.1200/JCO.2014.56.2785. Epub 2014 Jun 30. No abstract available.

PMID:
24982455
[PubMed - in process]
11.

Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.

Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, Bokemeyer C, Salat C, Scambia G, Berton-Rigaud D, Santoro A, Cervantes A, Trédan O, Tournigand C, Colombo N, Dudnichenko AS, Westermann A, Friccius-Quecke H, Lordick F.

Med Oncol. 2014 Aug;31(8):76. doi: 10.1007/s12032-014-0076-7. Epub 2014 Jun 26.

PMID:
24965536
[PubMed - in process]
12.

ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.

Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J; Australian Ovarian Cancer Study Group, Williams RT, Flemming C, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching P, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Nakanishi T, Yatabe Y, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan J, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut J, Iversen E, Weber RP, Berchuck A, Goode E, Bowtell DD, Chenevix-Trench G, deFazio A, Norris MD, MacGregor S, Haber M, Henderson MJ.

J Natl Cancer Inst. 2014 Jun 23;106(7). pii: dju149. doi: 10.1093/jnci/dju149. Print 2014 Jul.

PMID:
24957074
[PubMed - indexed for MEDLINE]
13.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM.

Lancet Oncol. 2014 Jul;15(8):799-808. doi: 10.1016/S1470-2045(14)70244-X. Epub 2014 Jun 17.

PMID:
24950985
[PubMed - indexed for MEDLINE]
14.

Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study.

Testa A, Kaijser J, Wynants L, Fischerova D, Van Holsbeke C, Franchi D, Savelli L, Epstein E, Czekierdowski A, Guerriero S, Fruscio R, Leone FP, Vergote I, Bourne T, Valentin L, Van Calster B, Timmerman D.

Br J Cancer. 2014 Aug 12;111(4):680-8. doi: 10.1038/bjc.2014.333. Epub 2014 Jun 17.

PMID:
24937676
[PubMed - in process]
15.

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).

Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.

Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001. Epub 2014 Jun 2.

PMID:
24889916
[PubMed - indexed for MEDLINE]
16.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U.

Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31.

PMID:
24882434
[PubMed - indexed for MEDLINE]
17.

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC Consortium.

Braicu EI, Van Gorp T, Nassir M, Richter R, Chekerov R, Gasimli K, Timmerman D, Vergote I, Sehouli J.

J Ovarian Res. 2014 May 7;7:49. doi: 10.1186/1757-2215-7-49. eCollection 2014.

PMID:
24872845
[PubMed]
Free PMC Article
18.

Reactive nodular fibrous pseudotumor: case report and review of the literature.

Salihi R, Moerman P, Timmerman D, Van Schoubroeck D, Op de Beeck K, Vergote I.

Case Rep Obstet Gynecol. 2014;2014:421234. doi: 10.1155/2014/421234. Epub 2014 Mar 30.

PMID:
24800089
[PubMed]
Free PMC Article
19.

Dendritic cell immunotherapy in uterine cancer.

Coosemans A, Tuyaerts S, Vanderstraeten A, Vergote I, Amant F, Van Gool SW.

Hum Vaccin Immunother. 2014 Apr 30;10(7). [Epub ahead of print]

PMID:
24784983
[PubMed - as supplied by publisher]
20.

Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.

Coosemans A, Vergote I, Van Gool SW.

Expert Rev Clin Immunol. 2014 Jun;10(6):705-11. doi: 10.1586/1744666X.2014.910119. Epub 2014 May 2.

PMID:
24784346
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk